database / incretin
Tirzepatide
also known as Mounjaro, Zepbound
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 166567236. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
Dual GIP/GLP-1 agonist built on a GIP-based backbone with Aib residues and a C20 diacid conjugate. Full primary structure not transcribed here rather than risked — see PubChem record.
Molecular data
| molecular formula | C225H348N48O68 |
|---|---|
| molecular weight | 4813 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 166567236 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Dual GIP and GLP-1 receptor agonist.
Reported targets: GIPR GLP-1R
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| weight loss | Decoding the hallmarks of GLP-1RA weight-loss super-responders Biology methods & protocols 2026 |
| glycaemic control | Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cance… Cureus 2026 |
| appetite suppression | Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated … Preprints.org 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT07720466 | Salivary Function and Dental Changes During GLP-1 Therapy | NOT_YET_RECRUITING | — |
| NCT07728812 | Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity P | NOT_YET_RECRUITING | NA |
| NCT06643728 | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298 | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07676331 | Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Pati | NOT_YET_RECRUITING | PHASE2 |
| NCT07559500 | Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | RECRUITING | PHASE1 |
Literature (8)
Decoding the hallmarks of GLP-1RA weight-loss super-responders — Biology methods & protocols 2026
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135 349 individuals treated with semaglutide and tirzepatide formulations and stratified them as "super responders" (>15% weight loss), "moderate responders" (5%-15% weight loss), "minimal weight-loss group" (P = .002) and osteoarthritis (RR = 0.5, P = .001) for Zepbound, and psoriasis (RR = 2.5, P = .03) for Wegovy. These results highlight significant heterogeneity in weight trajectories following sustained exposure to a GLP-1RA therapy and identify factors associated with increased weight loss, likely reflecting a combination of biological, behavioral, and social factors. These insights motivate further prospective analyses to help guide the development of more tailored weight-loss inte…
open access ↗ · PMID 42147968 · DOI 10.1093/biomethods/bpag021
Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review — Cureus 2026
[This corrects the article DOI: 10.7759/cureus.111445.].
open access ↗ · PMID 42388932 · DOI 10.7759/cureus.c457
Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age Patients — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202607.0809.v1
New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202607.1370.v1
Same Result, Different Price: Compounded versus Branded Tirzepatide — medRxiv 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.64898/2026.07.14.26357505
Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and Mounjaro — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202604.1175.v1
Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro) — Cureus 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42438627 · DOI 10.7759/cureus.110692
Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review — Cureus 2026
Tirzepatide, marketed as Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is widely used to treat type 2 diabetes and obesity. As more women presenting to screening and symptomatic breast clinics receive tirzepatide, questions have emerged regarding how rapid pharmacologic weight loss may influence breast lump detection, mammographic density, and breast cancer risk. This narrative review summarises tirzepatide pharmacology, its effects on adiposity, expected changes in breast composition with weight loss, oncologic data on breast cancer risk and outcomes, and radiological implications for mammography, ultrasound, and MRI. Randomised-trial data and meta-analyses currently show no clear evidence of increased breast cancer incidence with tirzepatide or GLP-1 receptor agonists. Preclinical studies in obesity-asso…
open access ↗ · PMID 42388957 · DOI 10.7759/cureus.111445
Related
Semaglutide
incretin · 8 citations
Retatrutide
incretin · 8 citations
Liraglutide
incretin · 8 citations
Exenatide
incretin · 8 citations
GLP-1 (7-37)
incretin · 8 citations
GIP
incretin · 8 citations